EPI-7386
EPI-7386 is an "N"-terminal domain antiandrogen, or antagonist of the "N"-terminal domain (NTD) of the androgen receptor (AR), which is under development for the treatment of prostate cancer. The compound was developed as a successor of previous drugs in the EPI series such as EPI-001, ralaniten (EPI-002), and ralaniten acetate (EPI-506). EPI-7386 shows 20-fold higher antiandrogenic potency than ralaniten "in vitro" ( = 535 nM vs. 9,580 nM, respectively), as well as greater stability in human hepatocytes. It is planned to enter phase I clinical trials in 2020.
Q25091755
"N"-terminal domain antiandrogen
Concept
Q410943
antagonist
Concept
Q284398
"N"-terminal domain
MISC
Q416601
androgen receptor
Concept
Q181257
prostate cancer
Concept
Q15408409
EPI-001
UNK
Q39050151
ralaniten
UNK
Q25091555
ralaniten acetate
UNK
Q574820
antiandrogen
Concept
Q2066956
potency
Concept
Q221681
in vitro
Concept
Q827450
hepatocyte
Concept
None
phase I
UNK
Q30612
clinical trial
Concept
Q96376837
EPI-7386
MISC
Q96376837
EPI-7386
MISC
2020-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
2020
DATE
-7386^^http://www.w3.org/2001/XMLSchema#decimal
-7386
NUMBER
-001^^http://www.w3.org/2001/XMLSchema#decimal
-001
NUMBER
-002^^http://www.w3.org/2001/XMLSchema#decimal
-002
NUMBER
-506^^http://www.w3.org/2001/XMLSchema#decimal
-506
NUMBER
-7386^^http://www.w3.org/2001/XMLSchema#decimal
-7386
NUMBER
+20^^http://www.w3.org/2001/XMLSchema#decimal
20
NUMBER
subclass of